FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or HER2-ultralow Breast Cancer By Ogkologos - March 6, 2025 554 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DESTINY-Breast06 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR FDA Approves Tremelimumab in Combination with Durvalumab for Unresectable Hepatocellular Carcinoma October 27, 2022 New reports show staff shortages continue to hold back cancer care June 9, 2022 Study Shows That Fast-Mimicking Diets Are Safe and Effective for Patients... July 20, 2020 NICE doesn’t recommend ibrutinib drug for those with Waldenstrom’s macroglobulinaemia May 23, 2022 Load more HOT NEWS Pembrolizumab Does Not Prolong Overall Survival Compared to Chemotherapy in Platinum-Pretreated... Adjuvant Pembrolizumab Plus Chemotherapy Improves DFS in Patients with Newly-Diagnosed, High-Risk... Targeted Therapy–Immunotherapy Combinations Effective for Advanced Kidney Cancer GENIE Registry Identifies Cancer Types Enriched with KRASG12C Somatic Mutations
